title: Plasmapheresis and subsequent pulse cyclophosphamide versus pulse cyclophosphamide alone in severe lupus: design of the LPSG trial. Lupus Plasmapheresis Study Group (LPSG).
abstract: A group of clinics are collaborating in the Lupus Plasmapheresis Study Group (LPSG) to investigate whether repeated plasmapheresis prior to pulse cyclophosphamide improves the therapeutical results in severe systemic lupus erythematosus (SLE). The underlying rationale is the hypothesis that plasmapheresis 1) eliminates pathogenic autoantibodies and immune complexes and 2) induces compensatory lymphocyte activation via feedback mechanisms between circulating antibodies and their respective clones ("antibody rebound"). It should be possible to utilize this enhanced activity for increased clonal deletion if pulse cyclophosphamide is applied shortly after plasmapheresis. Accordingly, in a randomized study, the LPSG will be comparing the repeated application of pulse cyclophosphamide alone with a treatment involving repeated plasmapheresis prior to the cyclophosphamide pulses in severe SLE. A third arm of the study will be gathering experience with a more intensified procedure. This overview summarizes the most important details of the planned study.
authors.affiliation: Study Surveillance Committee, Clinical Coordinating Center, Kiel, Federal Republic of Germany.
authors.forename: W F
authors.initials: WF
authors.lastname: Clark
authors.forename: P C
authors.initials: PC
authors.lastname: Dau
authors.forename: H H
authors.initials: HH
authors.lastname: Euler
authors.forename: L
authors.initials: L
authors.lastname: Guillevin
authors.forename: J
authors.initials: J
authors.lastname: Hasford
authors.forename: A H
authors.initials: AH
authors.lastname: Heer
authors.forename: J V
authors.initials: JV
authors.lastname: Jones
authors.forename: M
authors.initials: M
authors.lastname: Kashgarian
authors.forename: G
authors.initials: G
authors.lastname: Knatterud
authors.forename: C M
authors.initials: CM
authors.lastname: Lockwood
mesh_terms: D003131:Combined Modality Therapy; D003520:Cyclophosphamide / Q000008:administration & dosage* / Q000627:therapeutic use; D004334:Drug Administration Schedule; D006801:Humans; D008180:Lupus Erythematosus, Systemic / Q000188:drug therapy / Q000628:therapy*; D010956:Plasmapheresis; D012107:Research Design
chemical_list: D003520:Cyclophosphamide